Common TitleGS-236-0104
Official Title A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Stribilid Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/Cobicistat (GS-9350) Versus Atripla® (Efavirenz 600 mg/Emtricitabine 200 mg/Tenofovir Disoproxil Fumarate 300 mg) in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Phase Phase II
ClinicalTrials.gov NCT00869557
Categories Treatment-Naive
Funding
IndustryGilead Sciences
References
- Cohen C, Elion R, Ruane P, et al. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS. 2011;25:F7-12.